awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37448763-086F6EE7-7B67-4C3C-AFCE-2BA06C2AF180
Q37448763-086F6EE7-7B67-4C3C-AFCE-2BA06C2AF180
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37448763-086F6EE7-7B67-4C3C-AFCE-2BA06C2AF180
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.
P2860
Q37448763-086F6EE7-7B67-4C3C-AFCE-2BA06C2AF180
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37448763-086F6EE7-7B67-4C3C-AFCE-2BA06C2AF180
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4b7d8a8acb00cf0ebccccb8c5dc5a1365c6865be
P2860
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets